Risk Factors for Long-Term Health-Related Quality-of-Life and Mental Health Outcomes in Traumatic Brain Injury: A Systematic Review and Meta-Analysis.

J NeurotraumaMar 24, 2026 (epub)
Clinical ResearchNeurologyPsychiatry

Zemedu Ferede, Sue Patterson, John Perera et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined early risk factors for long-term mental health and health-related quality-of-life outcomes in adults with traumatic brain injury (TBI), using studies with outcomes assessed at least 6 months after discharge. Among 64 studies involving 334,672 participants, female sex, socioeconomic disadvantage, psychiatric history, assault-related injury, and previous TBI were consistently associated with poorer outcomes. For post-traumatic stress disorder, assault-related injury was associated with higher odds (OR = 2.72; 95% CI: 2.01-3.66, I² = 0%).

Key findings

  • Assault-related injury was associated with higher odds of post-traumatic stress disorder (OR = 2.72; 95% CI: 2.01-3.66, I² = 0%).
  • Higher odds of post-traumatic stress disorder were associated with female sex (OR = 1.33; 95% CI: 1.11-1.59, I² = 0%), prior TBI, and psychiatric history.
  • Depression was associated with female sex (OR = 1.72; 95% CI: 1.38-2.16, I² = 58%), prior TBI (OR = 1.52; 95% CI: 1.25-1.85, I² = 0%), and psychiatric history (OR = 3.25; 95% CI: 1.86-5.69, I² = 98%).
  • Higher pooled anxiety scores were observed among females and people with a psychiatric history.

Why it matters

The findings identify factors available before or by discharge that are associated with later mental health and quality-of-life difficulties. Such evidence may help inform risk-stratified follow-up and future prognostic tools, while the reported heterogeneity and observational associations mean these factors should not be interpreted as causes or definitive individual predictions.

What to keep in mind

The review reports that the underlying literature was sparse and methodologically heterogeneous, limiting clinical applicability; heterogeneity was substantial for some pooled associations.

Source

Published in J Neurotrauma. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.